SEC Form 4 · accession 0001610717-26-000296
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack Anders
Officer — Chief Financial Officer
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 24, 2026 | M | 20,000 | $18.56 | A | 143,269 | D | |
| Common StockF3,F2 | Jun 24, 2026 | S | 4,553 | $167.345 | D | 138,716 | D | |
| Common StockF4,F2 | Jun 24, 2026 | S | 9,496 | $168.1959 | D | 129,220 | D | |
| Common StockF5,F2 | Jun 24, 2026 | S | 5,651 | $169.2441 | D | 123,569 | D | |
| Common StockF6,F2 | Jun 24, 2026 | S | 300 | $170.32 | D | 123,269 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $18.56 | Jun 24, 2026 | M | 20,000 | A | Mar 1, 2026 | Feb 29, 2032 | Common Stock | 20,000 | 20,600 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026.
- F2Includes 51,388 restricted stock units.
- F3This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.